Dr. John Cush RheumNow
2 years 10 months ago
ACR 2022 Guideline on Glucocorticoid-Induced Osteoporosis
The ACR has published its updated recommendations for prevention and treatment of GIOP for patients receiving >3 months treatment with glucocorticoids (GCs) ≥2.5 mg daily.
https://t.co/oKVovOafl7 https://t.co/irxsAxMwKA
Dr. John Cush RheumNow
2 years 10 months ago
#PMR and Telemedicine: do we really need an office visit?
Can we use a synchronous audiovisual visit or a rheumatology eConsult to evaluate the patient's symptoms quickly? Does it allow us to make an accurate diagnosis?
https://t.co/JTAYstzDk8 https://t.co/NNvYfdkm2K
JAK inhibitors obviously have dominated a lot of the discussion in our therapeutic landscape over the last couple of years. What about their use in polymyalgia rheumatica? Let's consider.
Dr. John Cush RheumNow
2 years 10 months ago
CMAJ analysis of 28 studies & 24 million pts Rx opioids suggest a higher risk of opioid overdose w/: high-dose opioids, fentanyl, multiple opioid Rxs, overdose Hx, Dx of substance use, depression, bipolar, mental illness, pancreatitis https://t.co/FprgoaTvXR https://t.co/G0QjNJTezu
A TNR Panel discussion on controversies in PMR: diagnosis, imaging, PCP roles, Lumping vs. Splitting.
Featuring Drs. Sarah Mackie, Wolfgang Schmidt, and Len Calabrese.
Moderated by Dr. David Liew.
Recorded on 10/24/2023
Dr. John Cush RheumNow
2 years 10 months ago
#PMR Polymyalgia rheumatica is very common, yet there is little research on the Dx & Management of PMR by #PCPs! Mayo study prevalence 701 per 100,000 (women=870 and men =508 per 100,000 population). https://t.co/7JZFeRPRnn https://t.co/0JoaXL4qv0
Dr. John Cush RheumNow
2 years 10 months ago
RheumNow Live registration is NOW OPEN! Early bird pricing through 11/30/2023.
https://t.co/Wdk4tvnlRz https://t.co/YFdvfbyrpJ
Narratives around polymyalgia rheumatica (PMR) often centre around “older people” or even “elderly”. And, indeed, the peak of the age distribution is in the mid-70s – not that everyone that age considers themselves old. Treating “young PMR” can be a very different proposition to treating someone in their seventies or eighties. It’s worth taking time to think this through.
Dr. John Cush RheumNow
2 years 10 months ago
Unpopular opinion: spinach can be bad for you
The title might have misled you; simply, Dr Stephen Paget’s analogy comparing the drastic response to steroids in #PMR to Popeye’s spinach stuck with me!
https://t.co/VNlY6O5YeE https://t.co/RZmbVL2EiZ
Dr. John Cush RheumNow
2 years 10 months ago
Methotrexate in OA
Dr. Jack Cush discusses the news, journal articles and regulatory actions. This week we discuss JAKne, DLE and SLE and more.
https://t.co/RHiRBxajc6 https://t.co/PCygEXKT8f
Dr. John Cush RheumNow
2 years 10 months ago
Subcutaneous Remsima, an infliximab biosimilar, has been FDA. Celltrion has rebranded this as Zymfentra, for maintenance therapy in adults with moderately to severely active Ulcerative colitis and Crohn's disease following (after giving IV infliximab) https://t.co/gvcssRuB92 https://t.co/dPYVi10KIA
